Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

CJC-1295 with DAC

Original CJC-1295 is a long-acting GHRH analogue using a drug-affinity-complex strategy. It should not be confused with short-acting modified GRF (1-29). Two small randomized ascending-dose studies in healthy adults reported sustained GH and IGF-1 increases; biomarker changes did not establish a therapeutic outcome.

Aliases reviewed
CJC-1295 DAC, CJC-1295
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedTwo small randomized studies in healthy adults, measuring hormone levels.
Animal/cell
Not rated
Approved medicine
None foundScope: the sources reviewed.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. It is studied for prolonged growth-hormone and IGF-1 exposure in endocrine pharmacology.

Identity

Original CJC-1295 is a long-acting GHRH analogue using a drug-affinity-complex strategy. It should not be confused with short-acting modified GRF (1-29).

Biological mechanism or research interest

It is studied for prolonged growth-hormone and IGF-1 exposure in endocrine pharmacology.

Verified approved human uses

No approved human use was verified in the reviewed sources.

Investigational human evidence

Two small randomized ascending-dose studies in healthy adults reported sustained GH and IGF-1 increases; biomarker changes did not establish a therapeutic outcome.

Muscle, fat-loss, recovery, sleep, and anti-aging claims are not demonstrated by endocrine biomarker elevations.

Human versus animal or cell evidence

Analogue design and receptor pharmacology inform duration but not clinical benefit.

Limitations and known risks

FDA cites limited clinical data and serious adverse events including increased heart rate and systemic vasodilatory reaction; impurities and immunogenicity are concerns.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.